The function of the Access & Product Management Advisory Committee (APMAC) is to advise MMV's Access team on appropriate strategies to achieve its goals.
The APMAC is composed of 10 to 20 members, nominated by the President and CEO. Members are appointed for 2 to 4 years, with appointments staggered so as to provide a rotating membership.
The members of the APMAC come from both industry and academia and cover the full range of expertise required to achieve access objectives.
APMAC Members
Dr Graciela Diap, Associate Staff of DNDi and FACT Medical Coordinator, Spain
Dr Susanna Hausmann-Muela, Chief Program Officer, Botnar Foundation, Switzerland
Dr Elizabeth Juma, WHO Inter-country Support Team for Eastern and Southern Africa
Dr. Corine Karema, Swiss TPHI, Switzerland; Malaria Expert on Global Fund TRP; former Dir NMCP, Rwanda
Ms Maeve Magner, MBA, Supply Chain Expert, USA | Ireland
Dr. Wilfrid Mbacham, Fellow CAS / AAS, Chair Dept of Physiology and Biochemistry, Univ of Yaoundé, Cameroon
Dr Kamini Mendis, Independent Consultant in Malaria and Tropical Medicine, Sri Lanka
Dr Melanie Renshaw, Chief Technical Advisor at ALMA, UK
Dr Martin De Smet, Coordinator of the Malaria Working Group of MSF (Médecins Sans Frontières)
Dr Richard W. Steketee, MD, MPH, Deputy Director, US President’s Malaria Initiative, USA; Chairman of MMV APMAC
Dr G.S Sonal, Additional Director and Head of Malaria Division of the National Vector Borne Disease Control Programme (NVBDCP), India
Prof Andy Stergachis, Professor of Epidemiology and Global Health, Adjunct Professor of Pharmacy and Health Services, Director of the Global Medicines Program, University of Washington, USA
Dr Brenda Waning, Chief, Global Drug Facility, Stop TB Partnership, Switzerland; and Vice-Chairman of MMV APMAC